DMAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
DiaMedica Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means DiaMedica Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .
DiaMedica Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means DiaMedica Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .
DiaMedica Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for DiaMedica Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
DiaMedica Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (NAS:DMAC) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
DiaMedica Therapeutics's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
DiaMedica Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DiaMedica Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of DiaMedica Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Jan Stahlberg | 10 percent owner | C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57 |
Scott Kellen | officer: CFO and Secretary | 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447 |
Randall Michael Giuffre | director | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Ab Trill | 10 percent owner | SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157 |
Richard D. Pilnik | director | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Dietrich John Pauls | director, officer: President and CEO | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Richard Ii Jacinto | 10 percent owner | 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417 |
David J. Wambeke | officer: Chief Business Officer | 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305 |
Private Ab Tomeqt | 10 percent owner | C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435 |
Koch Thomas Von | 10 percent owner | TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47 |
Ab Tomenterprise | 10 percent owner | C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27 |
Charles Pauling Semba | director | TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Richard Kuntz | director | MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432 |
Tanya Lewis | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459 |
Julie Vanorsdel Daves | officer: SVP Clinical Development Oper. | 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305 |
From GuruFocus
By Business Wire • 11-06-2023
By Business Wire Business Wire • 12-13-2021
By Business Wire • 09-12-2023
By Business Wire Business Wire • 10-31-2022
By Business Wire Business Wire • 06-21-2023
By Business Wire • 09-06-2023
By Business Wire • 07-18-2023
By Business Wire Business Wire • 04-28-2022
By Business Wire Business Wire • 10-26-2022
By Business Wire Business Wire • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.